Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients

被引：0
|
作者：
Sellem, B. [1 ]
Abdi, B. [2 ]
Peytavin, G. [3 ]
Tubiana, R. [1 ]
Valantin, M. -A. [1 ]
Seang, S. [1 ]
Schneider, L. [1 ]
Faycal, A. [1 ]
Soulie, C. [2 ]
Marcelin, A. -G. [2 ]
Katlama, C. [1 ]
Pourcher, V. [1 ]
Palich, R. [1 ]
机构：
[1] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Infect Dis Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France
[2] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Virol Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France
[3] Univ Paris, Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept,IAME,INSERM,UMRS 1137, Paris, France
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/23
引用
收藏
页码：90 / 91
页数：2
相关论文
共 50 条
  • [41] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients
    Cicalini, S.
    Lorenzini, P.
    Grilli, E.
    Plazzi, M. M.
    De Zottis, F.
    Camici, M.
    Fusto, M.
    Gagliardini, R.
    Bellagamba, R.
    Antinori, A.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [42] Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence
    Boffito, Marta
    Brunetta, Jason
    Levy, Itzchak
    Yang, Chia-Jui
    Portilla, Joaquin
    De Barra, Eoghan
    Vogelmann, Roger
    Endo, Tomoyuki
    Robineau, Olivier
    Sarmati, Loredana
    Thorpe, David
    Marongiu, Andrea
    Cassidy, Tali
    van Welzen, Berend
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 79 - 82
  • [43] Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in kidney transplant recipients living with HIV-1 receiving calcineurin and mTOR inhibitors: a pilot switch study
    Gallien, Sebastien
    Assoumou, Lambert
    Dantal, Jacques
    Hulin, Anne
    Benalycherif, Aida
    Ben Rayana, Raida
    Tobbal, Yasmine
    Matignon, Marie
    Melica, Giovanna
    Allavena, Clotilde
    Stehle, Thomas
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 286 - 287
  • [44] Patient-reported outcome measures at 12 months in a real-world cohort of people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
    Brunetta, Jason
    Monforte, Antonella
    van Welzen, Berend
    Milinkovic, Ana
    Marongiu, Andrea
    Heinzkill, Marion
    Thorpe, David
    Cornejo, Almudena Torres
    Antela, Antonio
    HIV MEDICINE, 2022, 23 : 76 - 76
  • [45] Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients
    Lagoutte-Renosi, Jennifer
    Flammang, Mylene
    Chirouze, Catherine
    Beck-Wirth, Genevieve
    Bozon, Fabienne
    Brunel, Anne-Sophie
    Drobacheff-Thiebaut, Marie-Christine
    Foltzer, Adeline
    Hustache-Mathieu, Laurent
    Kowalczyk, Jakub
    Michel, Catherine
    Davani, Siamak
    Muret, Patrice
    CURRENT HIV RESEARCH, 2021, 19 (01) : 84 - 89
  • [46] Modelling the long-term clinical outcomes of the novel single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the UK
    Hearmon, N.
    Matin, N.
    Painter, C.
    Robinson, C.
    Eddowes, L.
    Kearns, S.
    Jandu, S.
    Wild, L.
    HIV MEDICINE, 2019, 20 : 21 - 21
  • [47] Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir plus emtricitabine/tenofovir Disoproxil Fumarate (DTG plus F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)
    Avihingsanon, A.
    Lu, H.
    Leong, C. L.
    Hung, C. -C.
    Koenig, E.
    Kiertiburanakul, S.
    Lee, M. -P.
    Supparatpinyo, K.
    Zhang, F.
    Rahman, S.
    Brogan, M. D'Antoni
    Wang, H.
    Hindman, J.
    Martin, H.
    Baeten, J.
    Li, T.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 226 - 227
  • [48] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BTC/FTC/TAF) in ART-naive patients: real-world data from the ICONA cohort
    Tavelli, A.
    Marchetti, G.
    Vergori, A.
    Quiros-Roldan, E.
    Malagnino, V.
    Vichi, F.
    Lichtner, M.
    Nozza, S.
    Rossotti, R.
    Sarmati, L.
    Bai, F.
    Di Biagio, A.
    Antinori, A.
    Monforte, A. d'Arminio
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 62 - 63
  • [49] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adult patients living with HIV-1 in routine clinical practice: 6-month results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H. J.
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Robinson, C.
    Heinzkill, M.
    HIV MEDICINE, 2020, 21 : 17 - 17
  • [50] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar
    Al Soub, Hussam
    Al-khal, A. Latif M.
    Alsoub, Deema
    Awouda, Waleed
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2020, 2020
12345